Claudio Bordignon

Active 1987–2020

73
Papers
19,420
Citations
70
h-index
73
i10-index

Citations

Citations per year for Claudio Bordignon1988: 4 citations1989: 8 citations1990: 10 citations1991: 18 citations1992: 16 citations1993: 12 citations1994: 12 citations1995: 14 citations1996: 18 citations1997: 24 citations1998: 43 citations1999: 34 citations2000: 49 citations2001: 84 citations2002: 95 citations2003: 121 citations2004: 169 citations2005: 155 citations2006: 156 citations2007: 199 citations2008: 156 citations2009: 167 citations2010: 195 citations2011: 174 citations2012: 143 citations2013: 164 citations2014: 160 citations2015: 211 citations2016: 193 citations2017: 217 citations2018: 187 citations2019: 597 citations2020: 704 citations2021: 625 citations2022: 476 citations2023: 352 citations2024: 429 citations2025: 212 citations2026: 5 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,420 citing papers, 30.2% of this breakdownItaly: 807 citing papers, 10.1% of this breakdownChina: 671 citing papers, 8.4% of this breakdownGermany: 599 citing papers, 7.5% of this breakdownUnited Kingdom: 515 citing papers, 6.4% of this breakdownFrance: 438 citing papers, 5.5% of this breakdownNetherlands: 243 citing papers, 3% of this breakdownJapan: 216 citing papers, 2.7% of this breakdownCanada: 204 citing papers, 2.6% of this breakdownSpain: 169 citing papers, 2.1% of this breakdownSwitzerland: 163 citing papers, 2% of this breakdownAustralia: 151 citing papers, 1.9% of this breakdown
0%30.2%Other 17.6%

Fields

  • Medicine52.3%
  • Biochemistry, Genetics and Molecular Biology27.3%
  • Immunology and Microbiology16.1%
  • Neuroscience2.2%
  • Materials Science0.7%
  • Engineering0.6%
  • Other0.8%

Topics

  • CAR-T cell therapy research12.1%
  • Virus-based gene therapy research8.4%
  • Immune Cell Function and Interaction6.9%
  • Immunotherapy and Immune Responses4.7%
  • T-cell and B-cell Immunology4.2%
  • CRISPR and Genetic Engineering4%
  • Other59.7%

Coauthors

All papers

Open in search
  1. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells

    Authors: , , , , , , , , , , , , , , , , - Nature Medicine 2018 cited by 1,380

  2. IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors

    Authors: , , , , , , , , , , , , , , , - Blood 2012 cited by 606

  3. Lentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Claudio Bordignon, Fabio Ciceri, Attilio Rovelli, Maria Grazia Roncarolo, Alessandro Aiuti, Maria Sessa, Luigi Naldini - Science 2013 cited by 1,201

  4. Tumor-mediated liver X receptor-α activation inhibits CC chemokine receptor-7 expression on dendritic cells and dampens antitumor responses

    Authors: , , , , , , , , , , , , , , , , , - Nature Medicine 2009 cited by 330

  5. Loss of Mismatched HLA in Leukemia after Stem-Cell Transplantation

    Authors: , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2009 cited by 517

  6. CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma

    Authors: , , , , , , , , , , , , , , , , , , - Blood 2013 cited by 352

  7. The oxysterol–CXCR2 axis plays a key role in the recruitment of tumor-promoting neutrophils

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - The Journal of Experimental Medicine 2013 cited by 234

  8. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer

    Authors: , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2012 cited by 444

  9. The IL-1/IL-1 receptor axis and tumor cell released inflammasome adaptor ASC are key regulators of TSLP secretion by cancer associated fibroblasts in pancreatic cancer

    Authors: , , , , , , , , , , , , - Journal for ImmunoTherapy of Cancer 2019 cited by 94

  10. Gene Therapy for Immunodeficiency Due to Adenosine Deaminase Deficiency

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2009 cited by 1,004

  11. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I–II study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Michael Stadler, Evangelia Yannaki, Αthanasios Fassas, Αchilles Anagnostopoulos, Marco Bregni, Corrado Gallo Stampino, Paolo Bruzzi, Claudio Bordignon - The Lancet Oncology 2009 cited by 484

  12. HSV-TK Gene Transfer into Donor Lymphocytes for Control of Allogeneic Graft-Versus-Leukemia

    Authors: , , , , , , , , , , - Science 1997 cited by 1,181

  13. In vivo tracking of T cells in humans unveils decade-long survival and activity of genetically modified T memory stem cells

    Authors: , , , , , , , , , , , , , , , , , - Science Translational Medicine 2015 cited by 174

  14. CAR T Cells Redirected to CD44v6 Control Tumor Growth in Lung and Ovary Adenocarcinoma Bearing Mice

    Authors: , , , , , , , , - Frontiers in Immunology 2020 cited by 74

  15. Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation

    Authors: , , , , , , , , , , , , , , , , , , , , , - Leukemia 2014 cited by 146

  16. Correction of ADA-SCID by Stem Cell Gene Therapy Combined with Nonmyeloablative Conditioning

    Authors: , , , , , , , , , , , , , , , , - Science 2002 cited by 1,134

  17. Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in mice

    Authors: , , , , , , , , , , , , - Journal of Clinical Investigation 2006 cited by 226

  18. Extracellular NGFR Spacers Allow Efficient Tracking and Enrichment of Fully Functional CAR-T Cells Co-Expressing a Suicide Gene

    Authors: , , , , , , , , , , - Frontiers in Immunology 2018 cited by 85

  19. Generation of human memory stem T cells after haploidentical T-replete hematopoietic stem cell transplantation

    Authors: , , , , , , , , , , , , , , , , , - Blood 2015 cited by 133

  20. Tracking genetically engineered lymphocytes long-term reveals the dynamics of T cell immunological memory

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Science Translational Medicine 2015 cited by 113

  21. R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-α in primary CNS lymphoma

    Authors: , , , , , , , , , , , , , , , , , , , , - Blood 2019 cited by 54

  22. De Novo Design of a Tumor-Penetrating Peptide

    Authors: , , , , , , , , , - Cancer Research 2012 cited by 174

  23. Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs

    Authors: , , , , , , , , , , , , , , , , , , , - Nature 2006 cited by 757

  24. The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies

    Authors: , , , , , , , - Blood 2007 cited by 207